Results 61 to 70 of about 2,193 (158)

Safety, Tolerability, and Pharmacokinetics of a Novel Nitroimidazooxazole Antitubercular Agent in Healthy Adults: A Phase I Trial

MedComm, Volume 6, Issue 12, December 2025.
Mean blood drug concentration–time curves (linear and semi‐logarithmic) of JBD0131 in the (A) single‐dose group; (B) food‐affected group. ABSTRACT This study evaluated the safety, tolerability, and pharmacokinetics of JBD0131, a novel nitroimidazooxazole antitubercular agent, in healthy adults.
Jia Miao, Zhenling Wang, Zhenyu Ding, Huashan Shi, Yongping Qin, Tiantao Gao, Ning Jiang, Jianqing He, Manni Wang, Xiawei Wei   +9 more
wiley   +1 more source

Recent advances in drug therapy for tuberculosis

National Journal of Physiology, Pharmacy and Pharmacology
Despite global efforts to control and eradicate tuberculosis (TB), it remains a significant source of morbidity and mortality worldwide. Drug-resistant TB (DRTB) is a significant public health threat with implications for global health security, economic
Amit M Shah, Sachi V Shah
doaj   +1 more source

Advancing Tuberculosis Chemotherapy: Targeted Nanomedicines for the Mycobacterium TB Granuloma

Small, Volume 21, Issue 49, December 10, 2025.
This graphical abstract illustrates nanosystems used for targeted drug delivery into tuberculosis granulomas. It shows how targeting is influenced by size, pH, redox sensitivity, and surface charge. Various nanoparticles are incorporated with drugs to enhance penetration, stability, and release.
Shreya Ranjith Singh, Maya Mellisa Makatini, Thashree Marimuthu, Yahya Essop Choonara   +3 more
wiley   +1 more source

Extrapolation of lung pharmacokinetics of bedaquiline across species using physiologically‐based pharmacokinetic modelling

British Journal of Clinical Pharmacology, Volume 91, Issue 11, Page 3167-3178, November 2025.
Aims Bedaquiline (BDQ) is a first‐in‐class diarylquinoline (DARQ) and a potent anti‐tuberculosis drug, vital in combating multi‐drug resistant tuberculosis (TB). Understanding its lung pharmacokinetics (PK) across species is crucial for effective clinical translation.
Evangelos Karakitsios, Oscar Della Pasqua, Aristides Dokoumetzidis   +2 more
wiley   +1 more source

Antibiotic Resistance: A Genetic and Physiological Perspective

MedComm, Volume 6, Issue 11, November 2025.
The development of resistance to antimicrobials and their historical progression are depicted in this graphic. It draws attention to important biochemical, physiological, and genetic factors that contribute to AMR, such as the transmission of genes, the development of biofilms, and the inactivation of antibiotics.
Rania G. Elbaiomy, Ahmed H. El‐Sappah, Rong Guo, Xiaoling Luo, Shiyuan Deng, Meifang Du, Xiaohong Jian, Mohammed Bakeer, Zaixin Li, Zhi Zhang   +9 more
wiley   +1 more source

3-(5-Nitrofuran-2-yl)prop-2-en-1-one Derivatives, with Potent Antituberculosis Activity, Inhibit A Novel Therapeutic Target, Arylamine N-acetyltransferase, in Mycobacteria

Antibiotics, 2020
In this study, the inhibitory potential of 3-(5-nitrofuran-2-yl)prop-2-en-1-one derivatives was evaluated against a panel of bacteria, as well as mammalian cell lines to determine their therapeutic index.
Neha Agre, Nilesh Tawari, Arundhati Maitra, Antima Gupta, Tulika Munshi, Mariam Degani, Sanjib Bhakta   +6 more
doaj   +1 more source

Multicomponent Synthesis of Fluorine‐Containing Bioactive Compounds and Drugs

European Journal of Organic Chemistry, Volume 28, Issue 38, October 15, 2025.
Multicomponent reactions are robust synthetic tools to assamble complex polyheterocycles and other interesting molecular architectures with potential application in medicinal chemistry, including their fluorine‐containing analogues. Fluorine atoms placed strategically into bioactive molecules often enhance essential pharmacokinetic parameters like ...
Ivette Morales‐Salazar, Perla Islas‐Jácome, Leonardo D. Herrera‐Zuñiga, Samuel Couve‐Bonnaire, Philippe Jubault, Eduardo González‐Zamora, Jean‐Philippe Bouillon, Alejandro Islas‐Jácome   +7 more
wiley   +1 more source

Experience of piloting BPaLM/BPaL for DR-TB care at selected sites in Pakistan

IJTLD Open
BACKGROUND: Pakistan ranks fourth globally in terms of high drug-resistant TB (DR-TB) burden, with approximately one-third of cases resistant to fluoroquinolones.
M.A. Khan, A. Ismail, A. Ghafoor, N. Khan, N. Muzaffar, F. Zafar, A. Gupta, S. Foraida, S. Juneja, R. Fatima, A.W. Khan, S. Shahid, M.A. Khan   +12 more
doaj   +1 more source

Novel Treatment for Pre-XDR Tuberculosis Linked to a Lethal Case of Acute Myocarditis

Diagnostics
The management of resistant tuberculosis (tb) can be extremely difficult, especially in case of novel unpredicted complications. In this report, we present a case of a 48-year-old patient with pre-extensively drug-resistant (XDR) tb who received a ...
Serafeim-Chrysovalantis Kotoulas, Pavlos Poulios, Georgia Chasapidou, Elena Angeloudi, Triantafyllenia Bargiota, Maria Stougianni, Katerina Manika, Eleni Mouloudi   +7 more
doaj   +1 more source

Emapalumab for Maladaptive Interferon‐γ‐Mediated Inflammation in Drug Reaction With Eosinophilia and Systemic Symptoms Complicating First‐Line Antituberculosis Therapy

Pediatric Blood &Cancer, Volume 72, Issue 12, December 2025.
Yahya Almodallal, Daniel Whitehurst, Sing Sing Way, Jane Koo, Ashish R. Kumar   +4 more
wiley   +1 more source